OBJECTIVE: To describe (1) the institutional variability in study approval and willingness to obtain federal assurance documents for a federally supported, minimal risk health services research project conducted during the implementation of the Privacy Rule and federalwide assurances, and (2) the potential impact of such policy on selection of research subjects and generalizability of study results. DATA SOURCES: Primary data collection from 2001 to 2004. STUDY DESIGN: We provide a descriptive analysis of a prospective, observational, out-of-hospital study. STUDY SETTING: Twenty-seven pediatric receiving hospitals were approached for participation in a study validating a decision rule to identify seriously injured children involved in motor vehicle crashes in Los Angeles County. Two federal research policies, the Privacy Rule and the requirement for federalwide assurances, were implemented during the project. DATA COLLECTION: All 27 hospitals were sent an identical research protocol requesting approval to review charts of children transported to their facility. The research protocol included strict confidentiality protections, was noninterventional, did not alter the standard of care at the scene or at the hospital, and met requirements for waivers of both informed consent and the Health Insurance Portability and Accountability Act. Because the project was federally supported, all participating hospitals were required to have a federalwide assurance. The hospitals receiving the research protocol were the unit of analysis and outcomes included: approval of the research protocol, total number of days to study approval, and successfully obtaining a federalwide assurance. PRINCIPLE FINDINGS: Overall, 6 of 27 (22 percent) hospitals refused to participate in the study, all of which were community hospitals. The median time from submitting an application to study approval was 118 days (interquartile range 34-254, range 12-960 days) and time to study approval differed when hospitals were categorized by type and the presence of an institutional review board (p=.053). No institutional review resulted in a change in the basic study protocol, although one hospital required paramedic consent. Following intensive efforts to secure federalwide assurances, 12 of 27 hospitals (44 percent) possessed the necessary assurance to conduct the study. If all patients transported to hospitals that failed to obtain such an assurance were omitted, the sample size would have been reduced by 62 percent and would have excluded all children transported to community hospitals. CONCLUSIONS: There is substantial institutional variability in approval of a minimal risk observational study and in willingness to obtain a federalwide assurance, particularly among community hospitals. Federal research policy involving patient privacy and institutional assurances may be contributing to this variability, which can adversely affect selection of research subjects, disrupt population-based study design, and threaten the generalizability of study results.
OBJECTIVE: To describe (1) the institutional variability in study approval and willingness to obtain federal assurance documents for a federally supported, minimal risk health services research project conducted during the implementation of the Privacy Rule and federalwide assurances, and (2) the potential impact of such policy on selection of research subjects and generalizability of study results. DATA SOURCES: Primary data collection from 2001 to 2004. STUDY DESIGN: We provide a descriptive analysis of a prospective, observational, out-of-hospital study. STUDY SETTING: Twenty-seven pediatric receiving hospitals were approached for participation in a study validating a decision rule to identify seriously injured children involved in motor vehicle crashes in Los Angeles County. Two federal research policies, the Privacy Rule and the requirement for federalwide assurances, were implemented during the project. DATA COLLECTION: All 27 hospitals were sent an identical research protocol requesting approval to review charts of children transported to their facility. The research protocol included strict confidentiality protections, was noninterventional, did not alter the standard of care at the scene or at the hospital, and met requirements for waivers of both informed consent and the Health Insurance Portability and Accountability Act. Because the project was federally supported, all participating hospitals were required to have a federalwide assurance. The hospitals receiving the research protocol were the unit of analysis and outcomes included: approval of the research protocol, total number of days to study approval, and successfully obtaining a federalwide assurance. PRINCIPLE FINDINGS: Overall, 6 of 27 (22 percent) hospitals refused to participate in the study, all of which were community hospitals. The median time from submitting an application to study approval was 118 days (interquartile range 34-254, range 12-960 days) and time to study approval differed when hospitals were categorized by type and the presence of an institutional review board (p=.053). No institutional review resulted in a change in the basic study protocol, although one hospital required paramedic consent. Following intensive efforts to secure federalwide assurances, 12 of 27 hospitals (44 percent) possessed the necessary assurance to conduct the study. If all patients transported to hospitals that failed to obtain such an assurance were omitted, the sample size would have been reduced by 62 percent and would have excluded all children transported to community hospitals. CONCLUSIONS: There is substantial institutional variability in approval of a minimal risk observational study and in willingness to obtain a federalwide assurance, particularly among community hospitals. Federal research policy involving patient privacy and institutional assurances may be contributing to this variability, which can adversely affect selection of research subjects, disrupt population-based study design, and threaten the generalizability of study results.
Authors: Michaele C Christian; Jacquelyn L Goldberg; Jack Killen; Jeffrey S Abrams; Mary S McCabe; Joan K Mauer; Robert E Wittes Journal: N Engl J Med Date: 2002-05-02 Impact factor: 91.245
Authors: C L Bennett; A M Sipler; J P Parada; M B Goetz; J A DeHovitz; R A Weinstein Journal: J Acquir Immune Defic Syndr Date: 2001-04-01 Impact factor: 3.731
Authors: Hanna Ezzat; Sue Ross; Peter von Dadelszen; Tara Morris; Robert Liston; Laura A Magee Journal: BMC Health Serv Res Date: 2010-07-30 Impact factor: 2.655
Authors: Brian T Helfand; Anne K Mongiu; Claus G Roehrborn; Robert F Donnell; Reginald Bruskewitz; Steven A Kaplan; John W Kusek; Laura Coombs; Kevin T McVary Journal: J Urol Date: 2009-04-16 Impact factor: 7.450
Authors: Craig D Newgard; Gena K Sears; Thomas D Rea; Daniel P Davis; Ronald G Pirrallo; Clifton W Callaway; Dianne L Atkins; Ian G Stiell; Jim Christenson; Joseph P Minei; Carolyn R Williams; Laurie J Morrison Journal: Resuscitation Date: 2008-05-15 Impact factor: 5.262
Authors: Diane Ng; M Shayne Gallaway; Grace C Huang; Theresa Famolaro; Jennifer Boehm; Karen Stachon; Elizabeth A Rohan Journal: BMC Health Serv Res Date: 2021-03-17 Impact factor: 2.655
Authors: Kirk D Midkiff; Elizabeth B Andrews; Alicia W Gilsenan; Dennis M Deapen; David H Harris; Maria J Schymura; Francis J Hornicek Journal: Pharmacoepidemiol Drug Saf Date: 2016-04-19 Impact factor: 2.890